What's Behind Celgene's Spending Spree
Celgene (CELG) is making strikingly creative deals to keep pipelines filled with promising therapies, including Celgene's most recent partnership with stem cell player OncoMed (ONCO).
3 Lessons From Amarin's Failures in 2013
Amarin had an awful 2013, being marginalized by GlaxoSmithKline’s Lovaza, upcoming generic competition from Teva, and a new treatment from AstraZeneca. What three valuable lessons can we learn from Amarin’s decline?
Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today
Ligand Pharmaceuticals, ChemoCentryx, Medivation, and Teva could make health care headlines today. Here's why.
3 Biggest FDA Decisions of 2013
Sarepta Therapeutics, Ariad Pharmaceuticals, and Amarin saw the FDA backtrack on earlier decisions this year.